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Abstract 
Background: Malaria in pregnancy (MiP) remains a major public health challenge in areas of high malaria transmis-
sion. Intermittent preventive treatment in pregnancy (IPTp) with sulfadoxine-pyrimethamine (SP) is recommended 
to prevent the adverse consequences of MiP. The effectiveness of SP for IPTp may be reduced in areas where the 
dhps581 mutation (a key marker of high level SP resistance) is found; this mutation was previously reported to be 
common in the Tanga Region of northern Tanzania, but there are limited data from other areas. The frequency of 
molecular markers of SP resistance was investigated in malaria parasites from febrile patients at health centres (HC) in 
seven regions comprising the Lake and Southern Zones of mainland Tanzania as part of the ongoing efforts to gener-
ate national-wide data of SP resistance.
Methods: A cross-sectional survey was conducted in the outpatient departments of 14 HCs in seven regions from 
April to June, 2015. 1750 dried blood spot (DBS) samples were collected (117 to 160 per facility) from consenting 
patients with positive rapid diagnostic tests for malaria, and no recent (within past 2 months) exposure to SP or 
related drugs. DNA was extracted from the DBS, pooled by HC, and underwent pooled targeted amplicon deep 
sequencing to yield estimates of mutated parasite allele frequency at each locus of interest.
Results: The dhps540 mutation was common across all 14 sites, ranging from 55 to 98.4% of sequences obtained. 
Frequency of the dhps581 mutation ranged from 0 to 2.4%, except at Kayanga HC (Kagera Region, Lake Zone) where 
24.9% of sequences obtained were mutated. The dhfr164 mutation was detected only at Kanyanga HC (0.06%).
Conclusion: By pooling DNA extracts, the allele frequency of mutations in 14 sites could be directly determined on 
a single deep-sequencing run. The dhps540 mutant was very common at all locations. Surprisingly, the dhps581 was 
common at one health center, but rare in all the others, suggesting that there is geographic micro-heterogeneity in 
mutant distribution and that accurate surveillance requires inclusion of multiple sites. A better understanding of the 
effect of the dhps581 mutant on the efficacy of IPTp-SP is needed.
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Background
Malaria in pregnancy (MiP) remains a major public 
health challenge in areas of high malaria transmission. 
In pregnant women, malaria can cause mild to severe 
maternal anaemia, particularly in primigravid women, 
and placental infection can interfere with the maternal-
fetal exchange of nutrients and oxygen, leading to pre-
term delivery and low birth weight, and consequently 
increasing neonatal mortality [1, 2]. In order to prevent 
the adverse consequences of MiP, the World Health 
Organization (WHO) recommends the use of intermit-
tent preventative treatment in pregnancy (IPTp) with 
sulfadoxine-pyrimethamine (SP)—a full treatment dose 
administered to pregnant women during routine ANC 
visits in the 2nd and 3rd trimesters. IPTp has a protective 
efficacy of nearly 25% against low birth weight and 21% 
against neonatal mortality [3].
Plasmodium falciparum resistance to SP results from 
an ordered accumulation of mutations in two genes, 
namely P. falciparum dihydrofolate reductase (Pfdhfr) 
and P. falciparum dihydropteroate synthase (Pfdhps) that 
code for enzymes targeted by sulfadoxine and pyrimeth-
amine, respectively. Resistance increases with the num-
ber of mutant alleles. The presence of five mutant alleles, 
the dhfr/dhps “quintuple mutant”, including the dhfr 
substitutions N51I, C59R, and S108N and the dhps sub-
stitutions A437G and K540E, are associated with a very 
high rate of failure when SP is used for the treatment 
of uncomplicated falciparum malaria [4]. However, SP 
remains effective for IPTp, even where the prevalence of 
the quintuple mutant is high, and thus its use continues 
to be recommended by the WHO [5, 6]. The efficacy of 
SP for IPTp appears to be compromised in the presence 
of a sixth mutation at dhps581 (sextuple mutant; A581G); 
infection with parasites harbouring the sextuple mutant 
has been associated with increased placental parasitae-
mia and inflammation and failure of IPTp-SP to improve 
birth weight [7–9].
Previous studies have reported that the dhps 581 muta-
tion is common in Tanga Region of Tanzania, with up to 
57% of parasites harbouring the sextuple mutant [10]; 
however, there are limited data from other areas of Tan-
zania. In light of the possibility that IPTp-SP may pro-
vide no benefit to women in areas with a high prevalence 
of the sextuple mutant, it is critical to define the extent 
of this mutation. This study aimed to investigate the 
prevalence of the SP resistance mutations dhps K540E 
(a surrogate marker for quintuple mutant [4]) and dhps 
A581G [9] and dhfr I164L [1] (surrogate markers for 
sextuple mutant parasites, with A581G being the more 
widely reported) in the parasite population in the Lake 
Zone (Mwanza, Geita, Mara, and Kagera Regions) and 
Southern Zone (Lindi, Mtwara, and Ruvuma Regions) of 
Tanzania.
Methods
Study area
From April to June, 2015, a cross-sectional survey was 
conducted in 14 health facilities (HFs) in seven regions 
of mainland Tanzania: all four regions in the Lake Zone 
(Mwanza, Geita, Mara, and Kagera) and all three regions 
in the Southern Zone (Lindi, Mtwara, and Ruvuma 
Regions) (Fig.  1). These regions were selected as they 
had high prevalence of malaria in the 2011/12 Tanzania 
HIV and Malaria Indicator Survey (THMIS) [11]. In each 
region, two health facilities were conveniently sampled 
from facilities with laboratory and where staff had been 
previously trained on collection of malaria rapid diagnos-
tic tests (RDTs) for other projects to determine whether 
the dhpsA581G mutation was present in these regions.
Sample size
It was estimated that a sample size of 100 malaria positive 
patients from each facility would produce a two-sided 
95% confidence interval of 1.6–11.3%, assuming the true 
proportion of patients infected with a given mutation was 
5%. To account for false positive results that may arise by 
use of RDTs, the target sample size was inflated by 20% to 
approximately 120 samples per facility.
Study population
All patients age ≥6 months presenting to the outpatient 
department who were diagnosed with malaria by RDT 
(Malaria Ag Pf/Pan, SD  Bioline®) or blood smear and no 
self-reported history of recent exposure to SP or trimeth-
oprim-sulfamethoxazole (within the past 2 months if not 
pregnant, or during the pregnancy, if pregnant) were con-
sented. In each health facility, consenting eligible patients 
were consecutively enrolled until the required number of 
DBS samples (120) were obtained.
Sample collection procedures
Two blood spots were collected on filter paper (Whatman 
no. 3, GE Healthcare Life Sciences) at the time the blood 
sample was collected for malaria testing; if the RDT was 
negative or the patient did not consent or otherwise did 
not meet inclusion criteria, the filter paper was destroyed 
(Fig.  2). Blood spots from consenting individuals were 
Keywords: Plasmodium falciparum, Sulfadoxine-pyrimethamine, Tanzania, Malaria, Resistance
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air dried for 3–4 h on a flat, nonabsorbent surface, then 
sealed in plastic bags with a desiccant, and stored at 
room temperature at the study health facility. The sam-
ples from all 14 health facilities were packaged in a water-
proof container, and shipped to the reference laboratory 
at the University of North Carolina (UNC) for pooled 
deep sequencing analyses at three genetic loci associ-
ated with sulfadoxine-pyrimethamine (SP) resistance, 
dhfr164, dhps540, and dhps581 [8, 12–14].
Molecular methods
Optimizing DNA extraction
120 Dried Blood Spots (DBS) from the Kharumwa health 
center were used in a preliminary experiment to deter-
mine if DNA from batched DBS could be extracted reli-
ably. Each subject’s DBS was punched 3 times. One of 
these punches was added to a single well of a 96-well 
plate. The other punches were pooled so that wells would 
contain either three or ten punches from individuals. 
The plate was extracted using the Chelex method using 
overnight incubation at 4  °C on a shaking platform at 
700 RPM (TPM2 shaker, Sarstedt, Nümbrecht, Ger-
many) [15]. After extraction, 3, 9 and 30  ml aliquots of 
supernatant were removed from the n =  1, n =  3, and 
n = 10 extracts, respectively, and combined with aliquots 
from similarly extracted samples: 1×: aliquots of all 120 
individually extracted samples; 3×: aliquots of all 40 of 
the 3-punch extracts; and 10×  aliquots of all 12 of the 
10-punch extracts.
Nested PCR amplification was done on each of the 
three DNA pools for dhps and dhfr using primers shown 
in Table  1 based on a previous report [16]. PCR condi-
tions were 95  °C × 2 min, followed by 40 rounds of [95 
°C × 30 s → 45 °C × 30 s → 72 °C × 1 min] and a final 
round of 72 °C for 10 m. Individual indexed libraries for 
each gene were made for each DBS pooling condition 
using the NEB Next Ultra DNA Library Prep Kit (New 
England Biolabs, Ipswich, USA) and pooled in equimo-
lar fashion. Pooled libraries were sequenced on an Illu-
mina MiSeq using 2  ×  300  bp reads at the UNC High 
Throughput Sequencing Facility. Allele frequencies for 
single nucleotide polymorphisms (SNPs) within the 
Fig. 1 Location of sampled health facilities with frequency of dhpsA581G mutations
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demultiplexed libraries were determined using methods 
previously described [17, 18].
Sequencing reads were aligned using bowtie2 with 
default settings to the P. falciparum 3D7 reference strain 
and the minor allele frequency (MAF) at all positions 
across the amplicon was determined using a revised ver-
sion of our previously described Minor Allele Catcher 
(MAC) [18]. Bases and reads were excluded from analysis 
if they had a mapping quality less than or equal to 10, a 
read length less than or equal to 200 bp, a base quality of 
less than or equal to 20, a base depth of less than or equal 
to 5000, if SNPs occurred in the first or last twenty-five 
bases of a read, or if 30% or fewer of the reads were on 
the forward or reverse strand.
Extraction and analysis of DBS from 13 other health centres
Based on the results of this pilot (Table  2), DNA from 
all of the remaining samples was extracted in batches of 
10 by health centre. The DNA extracts from each of the 
health centres were then pooled yielding one amplicon 
pool for each site (13 pools). Library preps and analy-
sis were performed as above. Data from the Kharumwa 
health centre, 10-punch extract, was re-run a second 
time to generate the 14-health center dataset.
Results
A total of 3575 febrile patients were screened, and 1770 
were found to be positive for malaria, yielding an over-
all positivity rate of 49.5% (Table  2). In this pilot work 
to determine the extraction efficiency of individual ver-
sus pooled extraction using the 120 participants from 
Kharumwa health centre, the proportion of mutant 
alleles varied only slightly as a result of batching DBS 
prior to extraction, with 9.4–10.7% alleles mutated at 
dhps540, 2.8–3.9% at dhps581, and none at dhfr164 
(Table 3). As these differences in allele frequencies were 
considered negligible, DBS from all other health centers 
were extracted in pools of 10.
A total of 1750 dried blood spot (DBS) samples were 
collected (117–160 samples per facility) and used in the 
final study analysis. Deep sequencing resulted in an aver-
age of 341,420 reads at dhfr (range 208,769–644,927) 
and 168,260 reads at dhps (range 49,419–313,645). The 
library from Kharumwa was re-sequenced during this 
project. Based upon this repeat sequencing (Table 4) and 
the 3 sequences in Table 3, the allele frequencies ±stand-
ard deviations for dhps540 and dhps581 mutants were 
90.0  ±  2.1% and 3.2  ±  0.7%, respectively. The dhps540 
mutation was common across all 14 sites, with allele 
frequency ranging from 55 to 98.4%, with higher allele 
frequency at sites in Lake Zone compared to South-
ern Zone (Table 4). Frequency of the dhps581 mutation 
ranged from 0 to 2.4%, with the exception of Kayanga 
health centre (Kagera Region, Lake Zone) where 24.9% of 
sequences were mutated (Fig.  1). The dhfr164 mutation 
was detected only at Kanyanga health centre (0.6%).
Discussion
In a survey of parasites from patients at 14 health facili-
ties in the Lake and Southern Zones of Tanzania, the 
dhpsK540E mutation was very common [in 10 facili-
ties (71%) more than 85% of alleles at dhpsK540E were 
mutated, and nowhere were fewer than 55% mutated], 
Blood sample for malaria 
BS/mRDT and DBS collected 
from every eligible patient
Meet 
Inclusion 
Criteria
Not eligible to 
participate. DBS 
discarded
DBS dried and stored at health facility
Malaria 
positive
Not eligible to 
participate. DBS 
discarded
DBS packaged and shipped to University 
of North Carolina for PCR analysis of SP 
resistance mutations
No
Yes
No
Yes
DBS collected from health facilities and 
transported to RTI office Dar es Salaam
Patients of all ages and gender 
suspected for malaria at the health 
facility
Fig. 2 Flowchart for recruiting participants and collecting samples. 
BS blood smear, DBS dried blood spot, RDT malaria rapid diagnostic 
test
Table 1 Primers
Primer Sequence Descrpition
Pfdhfr-F1 TCCTTTTTATGATGGAACAAG dhfr outer forward
Pfdhfr-R1 AGTATATACATCGCTAACAGA dhfr outer reverse
Pfdhfr1-F TGAGGTTTTTAATAACTACACATTTAGA 
GGTCT
dhfr inner forward
Pfdhfr1-R TCGCTAACAGAAATAATTTGATACTCAT dhfr inner reverse
Pfdhps-F1 AACCTAAACGTGCTGTTCAA dhps outer forward
Pfdhps-R1 AATTGTGTGATTTGTCCACAA dhps outer reverse
Pfdhps1-F TGAAATGATAAATGAAGGTGCTAGTGT dhps inner forward
Pfdhps1-R GTTGTGTATTTATTACAACATTTTGATCA 
TTC
dhps inner reverse
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while the dhpsA581G mutation remained rare and focal, 
with frequency greater than 2.4% in only one facility, Kay-
anga Health Facility, where nearly 25% of alleles carried 
the dhpsA581G mutation. The quintuple mutation (rep-
resented by the dhpsK540E) has been reported widely 
across Tanzania, with prevalence ranging from 64 to 98% 
in one recent report assessing seven regions [10] and 
77 to 95% in another [19]. Previous reports from Tanga 
Region have found a high prevalence of parasites har-
bouring the dhpsA581G mutation (44% in Korogwe [7], 
51% in Muheza [19], and 57% in Bondo [10]). Although 
the Lake and Southern Zones of Tanzania are not imme-
diately adjacent to Tanga Region, the absence of the 
dhpsA581G mutation in the majority of sites highlights 
that there may be considerable geographic micro-heter-
ogeneity. This is supported by data from Kavishe et  al., 
who similarly found the dhpsA581G to be present at high 
proportion in only Tanga and Kagera Regions, though the 
prevalence of mutants at their sites were higher than the 
allele frequencies reported here [10]. This is a reassuring 
finding, suggesting that IPTp-SP retains efficacy in the 
majority of Tanzania, but highlighting the need for moni-
toring in multiple geographic sites.
The pooling and sequencing methodology presented 
here is a cost-effective alternative to individual allele-spe-
cific PCR. Using this 2-step pooling methodology, it was 
possible to perform 90% fewer DNA extractions and 99% 
fewer sequencing runs than if samples from each par-
ticipant had been sequenced individually, saving a sub-
stantial amount of both time and money. The individual 
extraction and bi-directional Sanger sequencing of 1750 
samples would cost on the order of $19,000. Here the 
same data has been compiled for under $4000.
Another advantage of the pooling method is that it 
allows direct calculation of the allele frequency, rather 
than prevalence. That is, it calculates the percentage 
of the parasite population bearing the mutation rather 
than the prevalence of individuals bearing parasites with 
mutated alleles. From an evolutionary point of view, the 
allele frequency of a mutation is more important than 
prevalence of the mutation because it approximates the 
likelihood that a mosquito will become infected with a 
mutant parasite after exposure to a given population.
Allele frequency and prevalence can be different 
when mixed infections are present and when individu-
als have infections with varying levels of parasitaemia. 
Table 2 Malaria testing and positivity rates at selected health centres
Region District Health centre Tested Positive Malaria positivity rate (%)
Lake Zone
 Kagera Karagwe Kayanga 331 121 37
 Kagera Muleba Kaigara 292 120 41
 Mara Musoma Murangi 219 121 55
 Mara Tarime Sirari 310 122 39
 Geita Geita Katoro 238 122 51
 Geita Nyang′hwale Kharumwa 230 120 52
 Mwanza Misungwi Misasi HC 187 130 70
 Mwanza Sengerema Mwangika 332 121 36
Sub-total Lake Zone 2139 977 46
Southern Zone
 Lindi Lindi Rural Kitomanga 199 126 63
 Lindi Nachingwea Marambo 244 129 53
 Mtwara Masasi Nagaga 222 160 70
 Mtwara Mtwara Nanguruwe 215 138 64
 Ruvuma Songea Madaba 261 120 46
 Ruvuma Namtumbo Namtumbo 295 120 41
Sub-total Southern Zone 1436 793 55
Total 3575 1770 50
Table 3 Distribution of mutants using pools from individ-
ually extracted (1×), 3-punch extracted (3×) and 10-punch 
extracted (10×)
DNA pool Proportion of mutant alleles
Dhps540 Dhps581 Dhfr164
1× 88.5% (339/383) 2.8% (13/464) 0% (0/319)
3× 88.6% (1014/1145) 3.8% (52/1380) 0.3% (2/586)
10× 89.9% (563/626) 3.3% (25/765) 0% (0/401)
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Traditionally, prevalence data have to be transformed by 
a complex equation to yield predicted allele frequencies 
[20]. However, in general, the allele frequency approxi-
mates the prevalence of major strain in a human popula-
tion, barring any biases [16, 21].
This study has a number of limitations. Samples were 
collected only from the Lake and Southern Zones, nei-
ther of which are immediately adjacent to Tanga region, 
where the highest prevalence of the dhpsA581G have 
been reported, thus more studies in those areas are 
needed to better define the extent of the mutant. With 
regard to the pooling methodology employed here, while 
much more cost-effective and time-saving than tradi-
tional PCR, it is not possible to trace a parasite strain 
back to a participant. Also, some haplotypes tend to be 
amplified better than others, leading to PCR amplifica-
tion bias. However, newer barcoding methods, such as 
primer ID [22], compensate for amplification bias and 
could allow identification of individuals (although DNA 
would still have to be extracted from individual DBS).
While overall, these data are reassuring with respect to 
the efficacy of IPTp-SP, there are select areas with a high 
prevalence of the sextuple mutant, where IPTp-SP may no 
longer provide a useful benefit against malaria. Spread of 
this sextuple mutant will threaten the usefulness of SP for 
IPTp. Given the fact that the quintuple mutant is already 
found throughout Tanzania, and the sextuple mutant has 
been found in high prevalence in several sites, continued 
surveillance in multiple sites, particularly in and around 
Tanga and Kagera, is warranted to monitor for the spread 
of the sextuple mutant. The pooling technique presented 
here provides a highly efficient and cost effective means 
to screen many samples from multiple sites.
Conclusion
Although the quintuple mutant was very common at all 
sampled facilities, dhpsA581G remains geographically 
restricted, suggesting that IPTp-SP remains effective 
in most of Tanzania. However, additional surveillance, 
particularly in and around Tanga and Kagera Region 
is warranted. This can be achieved efficiently through 
sequencing pooled samples as described here. Finally, a 
better understanding of the effect of the dhps581 mutant 
on the efficacy of IPTp-SP is needed.
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